Pediatrix Medical Group, Inc. - 10-Q Summary (Q2 2002)
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2002. Pediatrix Medical Group, Inc. operates as a national provider of pediatric medical services, primarily through neonatal intensive care units and pediatric practices. The company continues to expand through acquisitions, including five physician group practices completed during the first half of 2002.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2002 | Six Months Ended June 30, 2001 |
|---|---|---|
| Net Patient Service Revenue | $223.5 million | $147.1 million |
| Net Income | $30.4 million | $10.0 million |
| Diluted EPS | $1.13 | $0.53 |
| Operating Income | $50.1 million | $19.5 million |
| Operating Margin | 22.4% | 13.2% |
| EBITDA | $53.0 million | $28.2 million |
| Cash and Cash Equivalents | $64.7 million | $4.4 million |
| Working Capital | $92.5 million | $34.4 million (Dec 31, 2001) |
| Total Debt (Current + Long-term) | $3.1 million | $3.2 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 52.0% year-over-year. Approximately 69.8% of this increase was driven by new units from acquisitions, while same-unit revenue grew 17.9% due to price increases, improved collections, and volume growth.
- Profitability Surge: Net income tripled to $30.4 million. A significant driver was the adoption of FAS 142, which eliminated goodwill amortization expense. Excluding amortization impacts in 2001, net income still increased by $15.2 million.
- Expense Management: Operating expenses rose 36.0%, primarily due to higher practice salaries and benefits ($43.0 million increase) linked to new acquisitions and staff growth. General and administrative expenses increased 27.2%, partly due to legal fees and settlement costs.
- Liquidity Improvement: Cash balances grew significantly from $27.6 million at year-end 2001 to $64.7 million, fueled by operating cash flows ($31.5 million) and proceeds from stock issuances ($27.8 million).
Guidance, Outlook, Risks, and Unusual Items
- Accounting Changes: The company adopted FAS 142 effective January 1, 2002, ceasing goodwill amortization. No goodwill impairment was identified during the initial testing in Q2 2002.
- Legal and Regulatory Contingencies:
- FTC Investigation: The company is cooperating with an FTC investigation regarding competition issues following the Magella merger; the outcome is unpredictable.
- Medicaid/State Investigations: A $1.3 million settlement was reached with Colorado regarding Medicaid billing. Investigations in Arizona and Florida were previously settled. A TRICARE investigation remains active, and inquiries from other states are ongoing.
- Securities Litigation: A $12.0 million settlement for a securities class action was approved in May 2002.
- Capital Allocation: In July 2002 (subsequent to the period end), the Board authorized a $35 million stock repurchase program. As of August 12, 2002, approximately 1.2 million shares were repurchased for $33.3 million.
- Outlook: Management expects funds from operations and the $100 million line of credit (currently with no outstanding balance) to be sufficient for working capital and capital expenditures for the next 12 months.
Investor Verification Checklist
- Verify the sustainability of same-unit revenue growth (17.9%) independent of acquisition activity.
- Monitor the status and potential financial impact of the ongoing FTC and TRICARE investigations.
- Assess the impact of the new stock repurchase program on future liquidity and share count.
- Review the integration progress of the five physician groups acquired in the first half of 2002.
- Confirm compliance with financial covenants on the $100 million line of credit, specifically regarding net worth and earnings.